Open Access

Predictors of cardiovascular disease in asthma and chronic obstructive pulmonary disease

  • Michela Bellocchia1,
  • Monica Masoero1,
  • Antonio Ciuffreda1,
  • Silvia Croce1,
  • Arianna Vaudano1,
  • Roberto Torchio2,
  • Monica Boita1 and
  • Caterina Bucca1Email author
Multidisciplinary Respiratory Medicine20138:58

DOI: 10.1186/2049-6958-8-58

Received: 21 May 2013

Accepted: 29 July 2013

Published: 3 September 2013

Abstract

Background

Cardiovascular disease (CVD) is a common comorbidity in patients with chronic airway obstruction, and is associated with systemic inflammation and airway obstruction. The aim of this study was to evaluate the predictors of CVD in two different conditions causing chronic airway obstruction, asthma and COPD.

Methods

Lung function tests, clinical and echocardiographic data were assessed in 229 consecutive patients, 100 with asthma and 129 with COPD. CVD was classified into: pressure overload (PO) and volume overload (VO). Sub-analysis of patients with ischemic heart disease (IHD) and pulmonary hypertension (PH) was also performed.

Results

CVD was found in 185 patients (81%: 51% COPD and 30% asthmatics) and consisted of PO in 42% and of VO in 38% patients. COPD patients, as compared to asthmatics, had older age, more severe airway obstruction, higher prevalence of males, of smokers, and of CVD (91% vs 68%), either PO (46% vs 38%) or VO (45% vs 30%). CVD was associated with older age and more severe airway obstruction both in asthma and COPD. In the overall patients the predictive factors of CVD were age, COPD, and male sex; those of PO were COPD, BMI, VC, FEV1 and MEF50 and those of VO were age, VC and MEF50. In asthma, the predictors of CVD were VC, FEV1, FEV1 /VC%, and PaO2, those of PO were VC, FEV1 and FEV1 /VC%, while for VO there was no predictor. In COPD the predictors of CVD were age, GOLD class and sex, those of VO age, VC and MEF50, and that of PO was BMI. Sub-analysis showed that IHD was predicted by COPD, age, BMI and FEV1, while PH (found only in 25 COPD patients), was predicted by VO (present in 80% of the patients) and FEV1. In subjects aged 65 years or more the prevalence of CVD, PO and VO was similar in asthmatic and COPD patients, but COPD patients had higher prevalence of males, smokers, IHD, PH, lower FEV1 and higher CRP.

Conclusions

The results of this study indicate that cardiovascular diseases are frequent in patients with chronic obstructive disorders, particularly in COPD patients. The strongest predictors of CVD are age and airway obstruction. COPD patients have higher prevalence of ischemic heart disease and pulmonary hypertension. In the elderly the prevalence of PO and VO in asthma and COPD patients is similar.

Keywords

Airway obstruction Asthma Cardiovascular disease COPD Pressure overload Volume overload

Background

Asthma and chronic obstructive pulmonary disease (COPD) are the most common airway disorders with a high morbidity and mortality [1, 2]. According to the Global Initiative for Asthma (GINA), approximately 300 millions people suffer from asthma [1] with a prevalence ranging from 1 to 18%. COPD prevalence is around 6%, but data are highly variable, depending on survey methods and diagnostic criteria [3].

Both asthma and COPD are characterized by inflammation, which in asthma, particularly the eosinophilic phenotype, is predominantly confined to the airway, while in COPD the inflammation may spill-over from the lungs to the systemic circulation and initiate systemic inflammation, as a consequence of exposure to indoor or outdoor air pollution, cigarette smoke, or diesel exhaust fumes [4]. A recent observation indicates that patients with neutrophilic asthma often have systemic inflammation [5]. Elevated serum levels of reactive C-reactive protein (CRP) are considered markers of systemic inflammation either in COPD or in asthma [5, 6]. Systemic inflammation may be pathogenically related to many of the comorbidities seen in chronic obstructive airway diseases, including cardiovascular disease (CVD). Cardiovascular complications in COPD have been attributed to the systemic effects of smoking [7]. Several observations suggest that reduced pulmonary function, no matter what cause, is associated with increases in myocardial infarction and arrhythmia [811]. Forced expiratory volume in one second (FEV1) is ranked second to smoking and above blood pressure and cholesterol as a predictor of all-cause and cardiovascular mortality [12]. In this regard, it has been suggested that a reduction in FEV1 combined with smoking history better predicts cardiovascular mortality than cholesterol [13].

The aim of this study was to evaluate prevalence and predictors of CVD in two common airway obstructive diseases with quite different phenotypes, asthma and COPD.

Methods

Consecutive adults outpatients with asthma and COPD, diagnosed according to international guidelines [1, 2], were recruited from those attending the Respiratory Pathophysiology clinic of the University Hospital San Giovanni, Turin, Italy, between January 2011 and June 2012. Inclusion criteria were: age over 40 years, no acute exacerbation of COPD and asthma in the last two months, no active pulmonary tuberculosis or other clinically relevant lung disease. Patients aged below 40 years were excluded because in this age range the risk of COPD is low [14].

Study design

Patients underwent recording of demographic data including age, full smoking history (current, former and never-smokers), recording of symptoms and medication use, clinical examination, assessment of lung function tests, arterial blood gas analysis and venous blood sampling for serum determination of CRP. Body mass index was calculated on the basis of height and weight (BMI) [15]. Asthma and COPD severity were classified according to GINA [1] and GOLD [2] criteria, respectively. Among COPD patients, those with predominant chronic bronchitis and predominant emphysema were identified.

Coexistent cardiovascular disease was assessed on the basis of history, clinical and echocardiographic data. CVD included: prior myocardial infarction and cardiovascular accidents, documented ischaemic heart disease, pulmonary or systemic arterial hypertension, heart valve disease, echocardiographic diagnosis of pulmonary hypertension.

According to the criteria of the American Heart Association [16], heart disease was classified as follows:

  • pressure overload (PO), causing diastolic dysfunction with preserved systolic function, including all the conditions causing concentric left ventricle hypertrophy, such as systemic arterial hypertension and aortic valve disease

  • volume overload (VO), including all the conditions causing left ventricle dilatation and systolic dysfunction, such as mitral or aortic incompetence and ischemic heart disease.

Sub-analysis was done on patients with ischemic heart disease (IHD) and pulmonary hypertension (PH).

Lung function tests were measured using the Baires System (Biomedin, Padua, Italy). The values of vital capacity (VC), forced expiratory volume in one second (FEV1), and their percentage ratio (FEV1/VC%), and maximum expiratory flow at mid VC (MEF50) were computed and expressed as percentage of the predicted value, according to the European Respiratory Society guidelines [17].

Arterial blood gases, that is oxygen and carbon dioxide partial pressures (PaO2 and PaCO2 respectively) were measured using the analyzer GEM 4000 PREMIERE (Instrumentation Laboratory Lexington USA).

Statistical analysis

Data were analyzed using the SPSS software package, version 20.0 (SPSS Inc., Chicago, IL, USA) for Windows. Discrete variables are presented as counts and percentages. Continuous variables are presented as means ± SEM, as appropriate. Comparisons between asthmatics and COPD patients, and between patients with predominant chronic bronchitis and predominant emphysema were performed by the unpaired Student's t-test. Comparisons among CVD, PO and VO patients with univariate ANOVA. Nominal variables were compared with the Fisher's exact test and Pearson’s χ2. A stepwise backward selection procedure was used to evaluate factors influent on heart disease, using a linear regression models. The models had as dependent variables CVD, PO or VO and as independent predictors: disease (asthma or COPD), age, sex, BMI, smoking habits, GINA or GOLD class, prebronchodilator lung function tests, PaO2, CRP. The same models were used to evaluate predictors for asthma and COPD separately and for the sub-analysis of patients with IHD or PH.

Statistical significance was assumed at p < 0.05.

Results

The subjects enrolled were 100 asthmatic patients and 129 COPD patients. CVD was found in 185 patients (81%), and consisted of pressure overload in 97 (42%) and of volume overload in 88 (38%). IHD was found in 58 patients (25%), 8 asthmatics and 50 COPD, and PH in 25 (11%), all with COPD. The general characteristics of asthmatic and COPD patients are compared in Table 1. The COPD group was older, and had higher prevalence of men and of both present and past smokers, more severe airway obstruction and higher prevalence of heart disease, including PO, VO, IHD and PH. Moreover, COPD patients had higher CRP values than asthmatics, suggestive of systemic inflammation. No significant difference in PaO2 and PaCO2 was found between the two groups.
Table 1

Comparison between general characteristics of patients with asthma and with COPD

 

ASTHMA N. 100

COPD N. 129

P

Age, years

59 ± 1.1

69 ± 0.9

< 0.0001

BMI

25.6 ± 0.5

26.2 ± 0.45

0.010

Male, n (%)

22 (22.0)

78 (60.5)

< 0.0001

Smokers

   

  current, n (%)

10 (10)

72 (55.8)

< 0.0001

  past, n (%)

8 (8)

42 (32.6)

< 0.0001

Atopy,n (%)

65 (73.1)

10 (7.7)

< 0.0001

Cardiovascular disease, n (%)

68 (68)

117 (90.7)

0.00002

  Pressure overload, n (%)

38 (38.0)

59 (45.7)

NS

  Volume overload, n (%)

30 (30.0)

58 (45.0)

0.021

  Subgroup IHD, n (%)

8 (8.0)

50 (38.8)

< 0.001

  Subgroup PH, n (%)

0 (0.0)

25 (19.4)

< 0.001

VC*, % predicted

88.9 ± 1.7

83.6 ± 1.8

0.033

FEV1*, % predicted

78.0 ± 2.0

64.6 ± 1.9

< 0.0001

FEV1/VC* %

65.7 ± 1.3

57.1 ± 1.3

< 0.0001

MEF50*, % predicted

41.8 ± 2.4

29.5 ± 2.1

< 0.0001

PaO2 , mmHg

74.5 ± 1.6

71.4 ± 1.0

NS

PaCO2 , mmHg

38.4 ± 0.5

39.8 ± 0.5

NS

CRP, mg/ml

3.4 ± 0.4

7.6 ± 0.7

< 0.0001

Beta adrenergic therapy, n (%)

94 (94.9)

97 (75.2)

0.0001

Corticosteroid therapy, n (%)

95 (96)

90 (69.8)

< 0.0001

Anticholinergic therapy, n (%)

22 (22)

76 (58.9)

<0.0001

Value recorded before bronchodilator.

The comparisons among subgroups with no cardiovascular disease (No CVD), with PO and VO in the overall patients, in asthma and in COPD are reported in the Tables 2, 3 and 4.
Table 2

Comparisons among patients without cardiovascular disease (no CVD), with pressure overload (PO) and volume overload (VO) in the overall study population

ASTHMA + COPD

no CVD N. 44

PO N. 97

VO N. 88

Univariate ANOVA

no CVD vs PO

no CVD vs VO

PO vs VO

Age, years

53.3 ± 1.3

64.3 ± 1.0

69.1 ± 1.1

< 0.0001

< 0.0001

< 0.0001

0.002

Male, n (%)

18 (40.9)

43 (44.3)

39 (44.3)

NS

NS

NS

NS

BMI

24.7 ± 0.7

26.9 ± 0.6

25.5 ± 0.5

0.038

0.028

NS

NS

VC, % pred.

93.4 ± 2.2

85.1 ± 1.7

83.5 ± 2.4

0.011

0.005

0.006

NS

FEV1, % pred.

82.6 ± 2.5

70.7 ± 2.1

64.8 ± 2.4

< 0.0001

0.001

< 0.0001

NS

FEV1/VC %

67.6 ± 1.7

61.5 ± 1.5

56.7 ± 1.6

< 0.0001

0.015

< 0.0001

0.032

MEF50, % pred

49.5 ± 4.1

35.8 ± 2.3

25.8 ± 2.3

< 0.0001

0.002

< 0.0001

0.003

CRP, mg/ml

3.1 ± 0.6

5.9± 0.6

7.3 ± 1.0

0.011

0.009

0.007

NS

NS not statistically significant.

Table 3

Comparisons among patients without cardiovascular disease (no CVD), with pressure overload (PO) and volume overload (VO) in asthma

ASTHMA

no CVD N. 32

PO N. 38

VO N. 30

Univariate ANOVA

no CVD vs PO

no CVD vs VO

PO vs VO

Age, years

51.3 ± 1.4

60.7 ± 1.6

63.1 ± 2.1

< 0.0001

< 0.0001

< 0.0001

NS

Male, n (%)

9 (28.1)

6 (15.8)

7 (23.3)

NS

NS

NS

NS

BMI

24.5 ± 0.8

26.5 ± 0.9

25.7 ± 0.7

NS

NS

NS

NS

VC, % pred.

94.0 ± 2.8

84.7 ± 2.2

89.0 ± 3.7

NS

0.011

NS

NS

FEV1, % pred.

85.4 ± 2.9

76.7 ± 2.9

73.8 ± 4.5

0.029

0.041

0.032

NS

FEV1/VC %

68.9 ± 1.7

65.7 ± 2.0

61.2 ± 2.9

0.042

NS

0.010

NS

MEF50, % pred

51.3 ± 4.2

37.8 ± 3.5

35.8 ± 4.5

0.017

0.016

0.015

NS

CRP, mg/ml

2.5 ± 0.5

4.1 ± 0.8

3.5 ± 0.8

NS

NS

NS

NS

Table 4

Comparisons among patients without cardiovascular disease (no CVD), with pressure overload (PO) and volume overload (VO) in COPD

COPD

no CVD N. 12

PO N. 59

VO N. 58

Univariate ANOVA

no CVD vs PO

no CVD vs VO

PO vs VO

Age, years

58.5 ± 2.6

66.7 ± 1.3

72.4 ± 1.0

< 0.0001

0.012

< 0.0001

0.001

Male, n (%)

9 (75)

37 (62.7)

32 (55.2)

NS

NS

NS

NS

BMI

25.4 ± 1.5

27.1 ± 0.7

25.4 ± 0.6

NS

NS

NS

NS

VC, % pred.

91.8 ± 3.12

85.3 ± 2.4

80.0 ± 2.9

NS

NS

NS

NS

FEV1,% pred

75.2 ± 4.8

66.3 ± 2.8

60.1 ± 2.8

0.048

NS

0.023

NS

FEV1/VC %

61.5 ± 3.8

58.8 ± 2.0

54.4 ± 1.9

NS

NS

NS

NS

MEF50, % pred

44.6 ± 10.2

34.5 ± 3.1

20.18 ± 2.1

< 0.0001

NS

< 0.0001

< 0.0001

CRP, mg/ml

4.4 ± 1.4

7.0 ± 0.9

8.9 ± 1.4

NS

NS

NS

NS

In the overall patients (Table 2), both PO and VO, as compared with no CVD, were associated with older age and lower VC, FEV1, FEV1/VC and MEF50 and higher CRP. The same associations (apart from CRP) were found in asthmatic patients (Table 3). In COPD patients (Table 4) the significant associations were with age and MEF50, %.

The results of linear regression analysis are shown in Table 5 for the whole patients, in Table 6 for asthmatic patients and in Table 7 for COPD patients. In the overall patients predictive factors of CVD were: age, COPD, and sex; those of PO were COPD, BMI, VC, FEV1 and MEF50 and those of VO were age, class of disease severity, VC and MEF50. In asthma, the strongest predictors of CVD were VC, FEV1 and FEV1 /VC%, and PaO2, those of PO were VC, FEV1 and FEV1 /VC%; no predictor was found for VO. In COPD the predictors of CVD were age, GOLD class and sex; those of VO were age, VC and MEF50, while the only predictor of PO was BMI.
Table 5

Results of linear regression analysis for predictors of cardiovascular disease (CVD) in the overall patients

Asthma + COPD

Non standardized coefficients

Standardized coefficient

t

Sig.

 

B

SD Error

β

  

CVD

     

Constant

.948

.248

 

3.829

.000

Age

.012

.003

.340

4.357

.000

COPD

.137

.063

.169

2.195

.030

Sex

.116

.058

.144

1.991

.048

VC, % pred

-.003

.002

-.124

−1.784

.076

MEF50, % pred

-.002

.001

-.131

−1.728

.086

Pressure overload

     

Constant

1.066

.264

 

4.031

.000

COPD

.217

.074

.225

2.939

.004

BMI

.017

.007

.183

2.482

.014

VC, % pred

-.006

.003

-.213

−2.031

.044

FEV1, % pred

.007

.003

.322

2.162

.032

MEF50, % pred

-.006

.002

-.305

−2.668

.008

Volume Overload

     

Constant

1.318

.446

 

2.954

.004

Age

.015

.004

.310

3.529

.001

GINA/GOLD class

-.118

.056

-.227

−2.113

.037

VC, % pred

-.006

.003

-.197

−2.244

.027

MEF50, % pred

-.005

.002

-.227

−2.094

.038

Table 6

Results of linear regression analysis for predictors of cardiovascular diseases (CVD) in asthma

ASTHMA

Non standardized coefficients

Standardized coefficient

t

Sig.

 

B

SD Error

β

  

CVD

     

Constant

8.291

1.056

 

7.851

.000

Age

-.009

.005

-.270

−1.981

.059

BMI

.016

.008

.223

1.874

.073

VC, % pred

−.060

.009

−2.402

−6.630

.000

FEV1, % pred

.073

.011

3.667

6.894

.000

FEV1/VC, %

−.094

.013

−3.499

−7.021

.000

PaO2

−.010

.005

−.278

−2.268

.033

PRC

.016

.009

.209

1.797

.085

Pressure Overload

     

Constant

6.668

1.082

 

6.163

.000

VC, % pred

−.060

.012

−1.874

−5.078

.000

FEV1, % pred

.067

.013

2.626

5.107

.000

FEV1/VC, %

−.077

.016

−2.237

−4.690

.000

Volume Overload

     

Constant

−.116

.693

 

−.167

.869

Age

.019

.011

.320

1.822

.079

Table 7

Results of linear regression analysis for predictors of cardiovascular diseases (CVD) in COPD

COPD

Non standardized coefficients

Standardized coefficient

t

Sig.

 

B

SD Error

β

  

CVD

     

Constant

.686

.393

 

1.747

.084

Age

.007

.003

.228

2.143

.035

GOLD Class

.076

.036

.241

2.089

.040

Sex

.121

.061

.203

1.983

.050

PaO2

.006

.003

.209

1.826

.071

Pressure Overload

     

Constant

1.237

.229

 

5.414

.000

BMI

.020

.008

.244

2.337

.022

Volume Overload

     

Constant

1.317

.519

 

2.539

.013

Age

.017

.005

.334

3.311

.001

VC, % pred

−.006

.003

−.220

−2.076

.041

MEF50, % pred

−.006

.003

−.305

−2.351

.021

As shown in Table 8, the predictors of IHD were COPD, age, BMI and FEV1 and those of PH, found only in COPD patients, were VO (present in 80% of the patients) and FEV1.
Table 8

Results of linear regression analysis for predictors of ischemic heart disease (IHD) and pulmonary hypertension (PH)

IHD

Non standardized coefficients

Standardized coefficient

t

Sig.

 

B

SD Error

β

  

IHD

     

Constant

−1.486

.667

 

−2.229

.028

COPD

.450

.134

.412

3.351

.001

Age

.012

.004

.246

2.834

.005

BMI

.016

.008

.177

2.095

.038

FEV1, % pred

.007

.003

.309

2.127

.036

GOLD class

.150

.083

.294

1.810

.073

PH

     

Constant

1.127

.244

 

4.613

.000

VO

.246

.045

.442

5.468

.000

GOLD class

−.105

.041

−.273

−2.584

.011

FEV1, % pred

−.004

.002

−.239

−2.222

.028

The distributions of PO and VO by severity of asthma (GINA) and COPD (GOLD) are reported in Figure 1. In asthma, there is a clear increase in the prevalence of both PO and VO with increasing the severity class, while in COPD the prevalence of each type of CVD is similar in all classes. The comparison between chronic bronchitis and emphysema patients, shown in Table 9, showed that the latter ones had older age, lower BMI, more severe airway obstruction and higher prevalence of heart volume overload and of pulmonary hypertension.
https://static-content.springer.com/image/art%3A10.1186%2F2049-6958-8-58/MediaObjects/40248_2013_Article_120_Fig1_HTML.jpg
Figure 1

Distributions of heart pressure overload (PO) and volume overload (VO) by GINA asthma severity class (left graph), and by GOLD COPD severity class (right graph).

Table 9

Comparison between general characteristics of patients with chronic bronchitis and emphysema

 

Chronic bronchitis

N. 102

Emphysema

N. 27

P

Age, years

68 ± 1.0

73 ± 1.5

0.017

BMI

27.2 ± 0.5

22.1 ± 0.6

< 0.0001

Male, n (%)

58 (56.9)

20 (74.1)

NS

Smokers

   

  current, n (%)

55 (53.9)

17 (63)

NS

  past, n (%)

33 (32.4)

9 (33.3)

NS

Cardiovascular disease, n (%)

92 (90.2)

25 (92.6)

NS

Pressure overload,n (%)

51 (50)

8 (29.6)

NS

Volume overload, n (%)

41 (40.2)

17 (63)

0.034

Subgroup IHD n (%)

39 (39.4)

11 (40.7)

NS

Subgroup PH n (%)

15 (4.7)

10 (37)

0.009

GOLD class

   

  1

30 (29.4)

1 (3.7)

0.005

  2

44 (43.1)

8 (29.6)

NS

  3

19 (18.6)

13 (48.1)

0.0016

  4

9 (8.8)

5 (18.5)

NS

VC, % predicted

82.7 ±2

85.5 ± 4.3

NS

FEV1, % predicted

68.1± 2.2

51.9 ± 3.1

0.001

FEV1/VC %

60.2 ± 1.4

46.56 ± 2.6

< 0.0001

MEF50, % predicted

33.7 ± 2.5

13.6 ± 2.1

< 0.0001

PaO2 , mmHg

71.2 ± 1.1

70.1 ± 2.1

NS

PaCO2 , mmHg

40.1 ± 0.6

39.0 ± 0.8

NS

CRP, mg/ml

7.9 ± 1.0

6.8 ± 1.2

NS

As one of the stronger predictors of CVD was age, we made a sub-analysis on subjects with an age equal to 65 years or higher. As shown in Table 10, the prevalence of CVD, PO and VO was similar in asthmatic and COPD patients; the latter had higher prevalence of men, smokers, lower FEV1, higher CRP and of IHD and PH. The results of linear regression analysis in these older patients are reported in Tables 11, 12 and 13.
Table 10

Comparisons between general characteristics of patients 65 years old or more

 

ASTHMA N. 33

COPD N. 92

P

Age, years

71.8 ± 0.8

73.6 ± 0.6

NS

Male, n (%)

5 (15.2)

60 (65.2)

< 0.0001

Smokers

   

Current n(%)

4 (13)

45 (51)

< 0.0001

Past n (%)

4 (13)

36 (41)

< 0.0001

BMI

25.8 ± 0.8

26.2 ± 0.5

NS

CVD, n (%)

30 (90.9)

87 (94.6)

NS

Pressure overload, n (%)

15 (45.5)

38 (41.3)

NS

Volume overload, n (%)

15 (45.5)

49 (53.3)

NS

Ischemic heart disease, n (%)

6 (18.2)

42 (46.7)

0.0054

Pulmonary hypertension, n (%)

0

21 (22.8)

0.0026

VC, % predicted

86.1 ± 2.6

82.7 ± 2.2

NS

FEV1, % predicted

73.3 ± 3.3

63.5 ± 2.3

0.023

FEV1/VC %

61.63 ± 2.5

56.4 ± 1.5

NS

MEF50, % predicted

30.8 ± 3.4

26.6 ± 2.3

NS

CRP, mg/l

4.1 ± 0.7

8.2 ± 1.0

0.018

Table 11

Results of linear regression analysis for predictors of cardiovascular disease in the overall patients 65 years old or more

Asthma + COPD

Non standardized coefficients

Standardized coefficient

t

Sig.

 

B

SD Error

β

  

CVD

     

Constant

.879

.421

 

2.087

.040

Age

.020

.006

.380

3.581

.001

VC, % predicted

−.005

.002

−.308

−2.813

.006

CRP

−.006

.003

−.190

−1.707

.092

Pressure overload

     

Constant

.895

.328

 

2.731

.008

Sex

.217

.094

.255

2.310

.024

BMI

.022

.011

.226

2.047

.044

Volume overload

     

Constant

.293

.874

 

.335

.739

Age

.024

.011

.229

2.091

.040

VC, % predicted

−.006

.003

−.207

−1.883

.063

Table 12

Results of linear regression analysis for predictors of cardiovascular disease in asthmatic patients 65 years old or more

Asthma

Non standardized coefficients

Standardized coefficient

t

Sig.

 

B

SD Error

β

  

CVD

     

Constant

7.203

.662

 

10.885

.000

VC, % pred

−.058

.007

−2.909

−8.345

.000

FEV1, % pred

.064

.008

4.069

7.728

.000

FEV1/VC, %

−.084

.011

−3.472

−7.509

.000

Pressure overload

     

Constant

3.616

1.487

 

2.432

.035

Age

.028

.015

.250

1.913

.085

Sex

.864

.152

.864

5.691

.000

GINA class

−.380

.138

−.629

−2.766

.020

VC, % pred

−.032

.010

−1.209

−3.306

.008

FEV1, % pred

.033

.012

1.566

2.661

.024

FEV1/VC, %

−.043

.015

−1.333

−2.785

.019

PaO2

−.017

.006

−.392

−2.954

.014

Volume overload

     

Constant

.293

.874

 

.335

.739

Age

.024

.011

.229

2.091

.040

Table 13

Results of linear regression analysis for predictors of cardiovascular disease in COPD patients 65 years old or more

COPD

Non standardized coefficients

Standardized coefficient

t

Sig.

 

B

SD Error

β

  

CVD

     

Constant

.542

.464

 

1.169

.247

Age

.018

.006

.373

3.259

.002

BMI

.011

.006

.200

1.748

.085

VC,% predicted

−.003

.002

−.198

−1.724

.090

Pressure overload

     

Constant

1.110

.330

 

3.366

.001

BMI

.025

.012

.263

2.060

.044

Volume overload

     

Constant

.928

.480

 

1.932

.058

Sex

.384

.148

.341

2.598

.012

Smoking

.289

.112

.339

2.576

.013

VC, % predicted

−.006

.004

−.212

−1.763

.083

Discussion

The results of this study show that patients with chronic airway obstructive disorders, either asthma or COPD, have increased prevalence of cardiovascular diseases as compared to the general population of similar age [18]. The comparison between the two disorders, (see Table 1) showed that CVD, particularly with volume overload, was more frequent in COPD patients, who had also older age, higher BMI, heavy smoking history, increased CRP and greater airway obstruction. This finding is in agreement with prior observations that in COPD comorbidities are frequent and are sustained by systemic inflammation and by smoking [4, 6, 7]. The comparison among patients without CVD, with PO and VO, showed that both pressure and volume overload were associated with older age and increased airway obstruction, either in asthma or in COPD, (see Tables 2, 3 and 4). These findings are in agreement with prior observations in COPD [813, 19]. Unfortunately, relatively little research has been done in asthma [14]. It is generally believed that the link between asthma and CVD is less strong than that for COPD [14, 20, 21] and this applies particularly to ischemic heart disease in asthmatic males. By contrast, in women adult-onset asthma has been found to be a significant risk factor for IHD and stroke [21, 22]. Although only 8 of our asthmatic patients had IHD, as many as 6 of them (75%) were never smoking women. However, the strongest predictors of IHD were COPD, age, BMI and FEV1, as previously suggested [19, 23]. The strong association of COPD with IHD is attributed to the effect of cigarette smoking [1924], and about 90% of our COPD patients were past or present smokers. The subanalysis of COPD patients with predominant chronic bronchitis or emphysema, (see Table 9), showed that the emphysema phenotype was associated with older age, lower BMI, more severe airway obstruction and higher prevalence of pulmonary hypertension and of volume overload. Unfortunately, there are no data in the literature comparing CVD in the two COPD phenotypes.

As mentioned above, age and COPD were the strongest predictors of CVD, but the two factors were closely linked each other, as COPD patients were significantly older than asthmatics. To clarify this point, we performed a sub-analysis on patients with an age equal to or higher than 65 years. As shown in Table 10, older asthmatics had the same prevalence of CVD than COPD patients (91% versus 95%). However, also in the elderly, the prevalence of IHD and PH was higher in COPD. Pulmonary hypertension deserves a special comment. PH in COPD is classically attributed to severe hypoxia causing raised pulmonary pressures, but other factors such as endothelial dysfunction or left heart disease, are deemed to play a role [24]. In our patients, the predictors of PH were FEV1 and volume overload, suggesting that both airway obstruction and post capillary mechanisms participated in increased pulmonary vascular resistance. Actually, VO was present in 80% of patients with PH.

Conclusions

In conclusion, the results of this study indicate that cardiovascular disease are frequent in patients with chronic obstructive disorders, particularly COPD. The strongest predictors of CVD are age and severity of airway obstruction. In older patients the prevalence of CVD is similar in asthma and COPD, apart from ischemic heart disease and pulmonary hypertension, which are strongly associated with COPD.

Abbreviations

COPD: 

Chronic obstructive pulmonary disease

CVD: 

Cardiovascular disease

FEV1: 

Forced expiratory volume in one second

IHD: 

Ischemic heart disease

MEF50: 

Maximum expiratory flow at mid VC

PH: 

Pulmonary hypertension

PO: 

Heart pressure overload

VO: 

Heart volume overload

VC: 

Vital capacity.

Declarations

Authors’ Affiliations

(1)
Department of Medical Sciences, University of Turin
(2)
Cardiorespiratory Pathophysiology Department, AOU S, Luigi

References

  1. Global initiative for Asthma (GINA). Updated 2012. http://www.ginasthma.org
  2. The Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2013. http://www.goldcopd.org
  3. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM: Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006, 28: 523-532. 10.1183/09031936.06.00124605.View ArticlePubMedGoogle Scholar
  4. Sin DD, Wu L, Man SF: The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005, 127: 1952-1959. 10.1378/chest.127.6.1952.View ArticlePubMedGoogle Scholar
  5. Wood LG, Baines KJ, Fu J, Scott HA, Gibson PG: The Neutrophilic Inflammatory Phenotype Is Associated With Systemic Inflammation in Asthma. Chest. 2012, 142: 86-93. 10.1378/chest.11-1838.View ArticlePubMedGoogle Scholar
  6. Pinto-Plata VM, Mullerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, Celli BR: C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax. 2006, 61: 23-28.PubMed CentralView ArticlePubMedGoogle Scholar
  7. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF: Systemic effects of smoking. Chest. 2007, 131: 1557-1566. 10.1378/chest.06-2179.View ArticlePubMedGoogle Scholar
  8. Friedman GD, Klatsky AL, Siegelaub AB: Lung function and risk of myocardial infarction and sudden cardiac death. N Engl J Med. 1976, 294: 1071-1075. 10.1056/NEJM197605132942001.View ArticlePubMedGoogle Scholar
  9. Ebi-Kryston KL, Hawthorne VM, Rose G, Shipley MJ, Gillis CR, Hole DJ, Carmen W, Eshleman S, Higgins MW: Breathlessness, chronic bronchitis and reduced pulmonary function as predictors of cardiovascular disease mortality among men in England, Scotland and the United States. Int J Epidemiol. 1989, 18: 84-88. 10.1093/ije/18.1.84.View ArticlePubMedGoogle Scholar
  10. Ebi-Kryston KL: Respiratory symptoms and pulmonary function as predictors of 10-year mortality from respiratory disease, cardiovascular disease, and all causes in the Whitehall Study. J Clin Epidemiol. 1988, 41: 251-260. 10.1016/0895-4356(88)90129-1.View ArticlePubMedGoogle Scholar
  11. Gulsvik A, Hansteen V, Sivertssen E: Cardiac arrhythmias in patients with serious pulmonary diseases. Scand J Respir Dis. 1978, 59: 154-159.PubMedGoogle Scholar
  12. Mannino DM, Watt G, Hole D, Gillis C, Hart C, McConnachie A, Davey Smith G, Upton M, Hawthorne V, Sin DD, Man SF, Van Eeden S, Mapel DW, Vestbo J: The natural history of chronic obstructive pulmonary disease. Eur Respir J. 2006, 27: 627-643. 10.1183/09031936.06.00024605.View ArticlePubMedGoogle Scholar
  13. Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM: Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ. 1996, 313: 711-715. 10.1136/bmj.313.7059.711.PubMed CentralView ArticlePubMedGoogle Scholar
  14. Cazzola M, Puxeddu E, Bettoncelli G, Novelli L, Segreti A, Cricelli C, Calzetta L: The prevalence of asthma and COPD in Italy: a practice-based study. Respir Med. 2011, 105: 386-391. 10.1016/j.rmed.2010.09.022.View ArticlePubMedGoogle Scholar
  15. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med. 1998, 158: 1855-1867.
  16. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW: 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009, 119: 1977-2016.View ArticlePubMedGoogle Scholar
  17. Quanjer PhH (ed.): Standardized lung function testing. Report Working Party Standardization of Lung Function Tests. European Community for Coal and Steel. Bull Eur Physiopathol Respir. 1983, 19 (Suppl. 5): 1-95.Google Scholar
  18. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J: Heart disease and stroke statistics–2011 update: a report from the American Heart Association. Circulation. 2011, 123 (suppl 4): e18-e209.PubMed CentralView ArticlePubMedGoogle Scholar
  19. Mannino DM, Thorn D, Swensen A, Holguin F: Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008, 32: 962-969. 10.1183/09031936.00012408.View ArticlePubMedGoogle Scholar
  20. Schanen JG, Iribarren C, Shahar E, Punjabi NM, Rich SS, Sorlie PD, Folsom AR: Asthma and incident cardiovascular disease: the Atherosclerosis Risk in Communities Study. Thorax. 2005, 60: 633-638. 10.1136/thx.2004.026484.PubMed CentralView ArticlePubMedGoogle Scholar
  21. Onufrak SJ, Abramson JL, Austin HD, Holguin F, McClellan WM, Vaccarino LV: Relation of adult-onset asthma to coronary heart disease and stroke. Am J Cardiol. 2008, 101: 1247-1252. 10.1016/j.amjcard.2007.12.024.PubMed CentralView ArticlePubMedGoogle Scholar
  22. Iribarren C, Tolstykh IV, Miller MK, Sobel E, Eisner MD: Adult Asthma and Risk of Coronary Heart Disease, Cerebrovascular Disease, and Heart Failure: A Prospective Study of 2 Matched Cohorts. Am J Epidemiol. 2012, 176: 1014-1024. 10.1093/aje/kws181.View ArticlePubMedGoogle Scholar
  23. de Lucas-Ramos P, Izquierdo-Alonso JL, Rodriguez-Gonzalez Moro JM, Frances JF, Lozano PV, Bellón-Cano JM: Chronic obstructive pulmonary disease as a cardiovascular risk factor. Results of a case-control study (CONSISTE study). Int J Chron Obstruct Pulmon Dis. 2012, 7: 679-686.PubMed CentralPubMedGoogle Scholar
  24. Stone IS, Barnes NC, Petersen SE: Chronic obstructive pulmonary disease: a modifiable risk factor for cardiovascular disease?. Heart. 2012, 98: 1055-1062. 10.1136/heartjnl-2012-301759.View ArticlePubMedGoogle Scholar

Copyright

© Bellocchia et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement